What is NDC 65219-346?

65219-346 is the product NDC for Glycophos (sodium glycerophosphate), Sodium glycerophosphate anhydrous 216 mg/mL injection, solution, listed with the FDA by Fresenius Kabi USA, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Glycophos (Sodium Glycerophosphate).

What is the active ingredient?

Sodium glycerophosphate anhydrous.

Fresenius Kabi USA, LLC, NDC labeler code 65219. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Glycophos?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Glycophos NDC 65219-346 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)65219-346Labeler and product segments. Claims need a package NDC.

Product NDC at billing width65219-0346Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
65219-346-20	6521903462065219034620	25 VIAL, SINGLE-DOSE in 1 CARTON (65219-346-20) / 20 mL in 1 VIAL, SINGLE-DOSE (65219-346-01)Marketed from Jul 29, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Glycophos
Generic name (nonproprietary): sodium glycerophosphate
Active ingredients: Sodium glycerophosphate anhydrous — 216 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Fresenius Kabi USA, LLCNDC labeler code 65219
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 220381
Marketing start: Jul 29, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 65219-346_05761514-5960-44b8-8e1d-7f0a1ceeee2aSPL ID 05761514-5960-44b8-8e1d-7f0a1ceeee2aSPL set ID e887e473-f1a7-40f1-bd6e-c99e7db7420dRxCUI 1423807, 1423812, 2754772, 2754775UNII YP1H63LJ2KUPC 0365219348016, 0365219346012

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N465219034620 followed by a unit qualifier and the quantity

Package 65219-0346-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 8, 2026.

Indications (excerpt from the label)

Glycophos is indicated as a source of phosphorus in adults and pediatric patients 12 years and older as part of parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. Glycophos is a phosphorus replacement product indicated as a source of phosphorus in adults and pediatric patients 12 years and older as part of parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 65219-346

What is NDC 65219-346?: 65219-346 is the product NDC for Glycophos (sodium glycerophosphate), Sodium glycerophosphate anhydrous 216 mg/mL injection, solution, listed with the FDA by Fresenius Kabi USA, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Glycophos (Sodium Glycerophosphate).
What is the active ingredient?: Sodium glycerophosphate anhydrous.
Who is the labeler?: Fresenius Kabi USA, LLC, NDC labeler code 65219. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Glycophos?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under NDA 220381

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 220381
Product	Strength	Form · route	Labeler	Product NDC
Glycophossodium glycerophosphate	Sodium glycerophosphate anhydrous 216 mg/mL	Injection, SolutionIntravenous	Fresenius Kabi USA, LLC	65219-348

Glycophos (Sodium glycerophosphate) NDC 65219-346